BioMarin Vimizim Heads to Committee in November, With Unusual Preview in September
This article was originally published in RPM Report
FDA’s new “Program” for NDA reviews emphasizes transparency with sponsors and key milestone dates in the review. BioMarin is one of the first companies to translate those milestones for investors.
You may also be interested in...
The Food & Drug Administration is approving the first products under the new PDUVA V review process. The Program, as it is known, gives FDA an extra two months with an application in exchange for additional meetings for sponsors. It’s designed to help reduce the number of late-cycle “surprises.” There have been a few hiccups, but so far, it appears to be doing just that.
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.